Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Net Income (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Net Income for 15 consecutive years, with $153.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income rose 49.08% year-over-year to $153.7 million, compared with a TTM value of $478.6 million through Dec 2025, up 40.23%, and an annual FY2025 reading of $478.6 million, up 40.23% over the prior year.
  • Net Income was $153.7 million for Q4 2025 at Neurocrine Biosciences, down from $209.5 million in the prior quarter.
  • Across five years, Net Income topped out at $209.5 million in Q3 2025 and bottomed at -$76.6 million in Q1 2023.
  • Average Net Income over 4 years is $79.1 million, with a median of $83.1 million recorded in 2023.
  • The sharpest move saw Net Income surged 156.66% in 2024, then tumbled 81.8% in 2025.
  • Year by year, Net Income stood at $30.5 million in 2021, then skyrocketed by 339.67% to $134.1 million in 2023, then decreased by 23.12% to $103.1 million in 2024, then skyrocketed by 49.08% to $153.7 million in 2025.
  • Business Quant data shows Net Income for NBIX at $153.7 million in Q4 2025, $209.5 million in Q3 2025, and $107.5 million in Q2 2025.